Supernus Pharmaceuticals Inc (SUPN)

$30.44

+0.54

(+1.81%)

Market is closed - opens 7 PM, 25 Jul 2024

Performance

  • $29.76
    $30.64
    $30.44
    downward going graph

    2.23%

    Downside

    Day's Volatility :2.87%

    Upside

    0.65%

    downward going graph
  • $21.99
    $35.44
    $30.44
    downward going graph

    27.76%

    Downside

    52 Weeks Volatility :37.95%

    Upside

    14.11%

    downward going graph

Returns

PeriodSupernus Pharmaceuticals IncSector (Health Care)Index (Russel 2000)
3 Months
-1.19%
5.5%
0.0%
6 Months
6.52%
7.2%
0.0%
1 Year
-0.5%
9.3%
0.0%
3 Years
9.16%
13.0%
-19.9%

Highlights

Market Capitalization
1.6B
Book Value
$16.91
Earnings Per Share (EPS)
-0.29
PEG Ratio
1.47
Wall Street Target Price
40.5
Profit Margin
-2.6%
Operating Margin TTM
-2.96%
Return On Assets TTM
0.23%
Return On Equity TTM
-1.68%
Revenue TTM
597.4M
Revenue Per Share TTM
10.93
Quarterly Revenue Growth YOY
-6.6000000000000005%
Gross Profit TTM
580.0M
EBITDA
90.6M
Diluted Eps TTM
-0.29
Quarterly Earnings Growth YOY
-0.99
EPS Estimate Current Year
1.75
EPS Estimate Next Year
2.1
EPS Estimate Current Quarter
0.38
EPS Estimate Next Quarter
0.4

Analyst Recommendation

Buy
    80%Buy
    20%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Supernus Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 33.05%

Current $30.44
Target $40.50

Company Financials

FY18Y/Y Change
Revenue
408.9M
↑ 35.29%
Net Income
111.0M
↑ 93.76%
Net Profit Margin
27.14%
↑ 8.19%
FY19Y/Y Change
Revenue
392.8M
↓ 3.95%
Net Income
113.1M
↑ 1.86%
Net Profit Margin
28.79%
↑ 1.65%
FY20Y/Y Change
Revenue
520.4M
↑ 32.5%
Net Income
127.0M
↑ 12.29%
Net Profit Margin
24.39%
↓ 4.4%
FY21Y/Y Change
Revenue
579.8M
↑ 11.41%
Net Income
53.4M
↓ 57.92%
Net Profit Margin
9.21%
↓ 15.18%
FY22Y/Y Change
Revenue
667.2M
↑ 15.09%
Net Income
60.7M
↑ 13.64%
Net Profit Margin
9.1%
↓ 0.11%
FY23Y/Y Change
Revenue
607.5M
↓ 8.95%
Net Income
1.3M
↓ 97.83%
Net Profit Margin
0.22%
↓ 8.88%
Q4 FY22Q/Q Change
Revenue
167.3M
↓ 5.65%
Net Income
25.5M
↑ 1356.89%
Net Profit Margin
15.23%
↑ 14.24%
Q1 FY23Q/Q Change
Revenue
153.8M
↓ 8.11%
Net Income
16.9M
↓ 33.49%
Net Profit Margin
11.02%
↓ 4.21%
Q2 FY23Q/Q Change
Revenue
135.6M
↓ 11.84%
Net Income
-831.0K
↓ 104.9%
Net Profit Margin
-0.61%
↓ 11.63%
Q3 FY23Q/Q Change
Revenue
153.9M
↑ 13.51%
Net Income
-16.0M
↑ 1822.5%
Net Profit Margin
-10.38%
↓ 9.77%
Q4 FY23Q/Q Change
Revenue
164.3M
↑ 6.78%
Net Income
1.2M
↓ 107.35%
Net Profit Margin
0.72%
↑ 11.1%
Q1 FY24Q/Q Change
Revenue
143.6M
↓ 12.58%
Net Income
124.0K
↓ 89.45%
Net Profit Margin
0.09%
↓ 0.63%
FY18Y/Y Change
Total Assets
977.8M
↑ 130.36%
Total Liabilities
524.8M
↑ 234.29%
FY19Y/Y Change
Total Assets
1.2B
↑ 18.66%
Total Liabilities
564.9M
↑ 7.63%
FY20Y/Y Change
Total Assets
1.5B
↑ 29.63%
Total Liabilities
759.2M
↑ 34.41%
FY21Y/Y Change
Total Assets
1.7B
↑ 12.3%
Total Liabilities
873.3M
↑ 15.02%
FY22Y/Y Change
Total Assets
1.7B
↑ 0.79%
Total Liabilities
816.3M
↓ 6.53%
FY23Y/Y Change
Total Assets
1.4B
↓ 17.24%
Total Liabilities
487.5M
↓ 40.28%
Q4 FY22Q/Q Change
Total Assets
1.7B
↑ 0.55%
Total Liabilities
816.3M
↓ 2.86%
Q1 FY23Q/Q Change
Total Assets
1.8B
↑ 5.25%
Total Liabilities
879.7M
↑ 7.76%
Q2 FY23Q/Q Change
Total Assets
1.3B
↓ 27.83%
Total Liabilities
373.2M
↓ 57.58%
Q3 FY23Q/Q Change
Total Assets
1.3B
↓ 0.61%
Total Liabilities
373.0M
↓ 0.06%
Q4 FY23Q/Q Change
Total Assets
1.4B
↑ 9.63%
Total Liabilities
487.5M
↑ 30.7%
Q1 FY24Q/Q Change
Total Assets
1.3B
↓ 7.44%
Total Liabilities
374.9M
↓ 23.09%
FY18Y/Y Change
Operating Cash Flow
129.0M
↑ 12.51%
Investing Cash Flow
-413.5M
↑ 378.48%
Financing Cash Flow
376.4M
↑ 6526.26%
FY19Y/Y Change
Operating Cash Flow
143.1M
↑ 10.96%
Investing Cash Flow
-157.9M
↓ 61.81%
Financing Cash Flow
3.9M
↓ 98.96%
FY20Y/Y Change
Operating Cash Flow
138.4M
↓ 3.3%
Investing Cash Flow
-34.7M
↓ 78.03%
Financing Cash Flow
3.6M
↓ 9.39%
FY21Y/Y Change
Operating Cash Flow
127.1M
↓ 8.14%
Investing Cash Flow
-81.9M
↑ 136.07%
Financing Cash Flow
-130.4M
↓ 3764.51%
FY22Y/Y Change
Operating Cash Flow
116.8M
↓ 8.1%
Investing Cash Flow
-216.7M
↑ 164.5%
Financing Cash Flow
-10.5M
↓ 91.97%
Q4 FY22Q/Q Change
Operating Cash Flow
27.6M
↑ 99.15%
Investing Cash Flow
-48.8M
↓ 40.7%
Financing Cash Flow
2.8M
↓ 56.17%
Q1 FY23Q/Q Change
Operating Cash Flow
49.1M
↑ 78.23%
Investing Cash Flow
239.8M
↓ 591.71%
Financing Cash Flow
80.2M
↑ 2734.0%
Q2 FY23Q/Q Change
Operating Cash Flow
-18.9M
↓ 138.42%
Investing Cash Flow
60.3M
↓ 74.85%
Financing Cash Flow
-478.9M
↓ 697.35%

Technicals Summary

Sell

Neutral

Buy

Supernus Pharmaceuticals Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Supernus Pharmaceuticals Inc
Supernus Pharmaceuticals Inc
11.11%
6.52%
-0.5%
9.16%
-8.79%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
8.85%
3.8%
45.41%
51.86%
68.72%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
2.31%
10.22%
1.49%
19.3%
19.3%
Zoetis Inc.
Zoetis Inc.
4.39%
-3.6%
-3.34%
-10.68%
55.39%
Viatris Inc.
Viatris Inc.
9.84%
-1.88%
8.29%
-16.91%
-29.62%
Catalent, Inc.
Catalent, Inc.
3.45%
17.64%
21.86%
-48.3%
5.41%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Supernus Pharmaceuticals Inc
Supernus Pharmaceuticals Inc
1500.0
NA
1.47
1.75
-0.02
0.0
NA
16.91
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
39.48
39.48
0.44
3.98
0.18
0.1
NA
23.72
Haleon Plc Spon Ads
Haleon Plc Spon Ads
29.73
29.73
1.69
0.39
0.07
0.04
0.02
1.8
Zoetis Inc.
Zoetis Inc.
34.83
34.83
2.58
5.77
0.5
0.14
0.01
11.07
Viatris Inc.
Viatris Inc.
224.4
NA
0.06
2.73
0.0
0.03
0.04
16.81
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.06
0.2
-0.28
-0.01
NA
19.96
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Supernus Pharmaceuticals Inc
Supernus Pharmaceuticals Inc
Buy
$1.6B
-8.79%
1500.0
-2.6%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$14.6B
68.72%
39.48
18.65%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$40.7B
19.3%
29.73
9.64%
Zoetis Inc.
Zoetis Inc.
Buy
$82.5B
55.39%
34.83
27.38%
Viatris Inc.
Viatris Inc.
Hold
$13.8B
-29.62%
224.4
-0.37%
Catalent, Inc.
Catalent, Inc.
Hold
$10.5B
5.41%
211.02
-28.44%

Insights on Supernus Pharmaceuticals Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 164.31M → 143.64M (in $), with an average decrease of 12.6% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 1.17M → 124.0K (in $), with an average decrease of 89.5% per quarter

  • Vs NBIX

    In the last 1 year, Neurocrine Biosciences Inc. has given 45.4% return, outperforming this stock by 45.9%

  • Vs NBIX

    In the last 3 years, Neurocrine Biosciences Inc. has given 47.6% return, outperforming this stock by 38.0%

Institutional Holdings

  • BlackRock Inc

    18.85%
  • Vanguard Group Inc

    11.29%
  • Armistice Capital, LLC

    6.50%
  • Macquarie Group Ltd

    4.86%
  • Dimensional Fund Advisors, Inc.

    4.65%
  • State Street Corporation

    3.71%

Company Information

pioneering new medicines in neurology and psychiatry with more than 20 years of experience, we are a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (cns) disorders. in 2013 we launched oxtellar xr® and trokendi xr®, two novel neurology products for the treatment of epilepsy. we are also developing several product candidates in psychiatry to address unmet medical needs and opportunities in attention-deficit hyperactivity disorder (adhd) and its coexisting disorders, and depression. we are developing differentiated products by leveraging our proprietary and in-licensed technologies. we use such technologies to discover and develop novel uses for known drug compounds and to enhance their therapeutic benefits. our focus on known drug compounds with established mechanisms of action reduces the risks, costs, and time typically associated with pharmaceutical product development.

Organization
Supernus Pharmaceuticals Inc
Employees
652
CEO
Mr. Jack A. Khattar
Industry
Health Technology

FAQs